| Name | Title | Contact Details |
|---|
Since 2007, Genalyte has been guided by the vision of taking a single drop of blood, performing panels of tests and returning accurate and reproducible results within a few minutes. We launched our first instrument in 2012 in the pharmaceutical industry and academia for a range of healthcare applications including autoimmune disease monitoring, screening of cancer biomarkers, testing for infectious agents and detecting anti-drug antibodies. By reducing tests to a microscopic size in a highly multiplex environment on the surface of silicon chips we are able to generate more information from a smaller sample in less time than conventional techniques.
Otsego Memorial Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Gaylord, MI. To find more information about Otsego Memorial Hospital, please visit www.myomh.org
Bridgemedica is a Walpole, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We`ve pioneered digital behavioral medicine: a new approach to tackling the growing epidemic of type 2 diabetes, heart disease, and obesity. Our online programs combine world-class science, technology, and design to inspire and enable people everywhere to live free of chronic disease. Named one of Fast Company`s “50 Most Innovative Companies in the World,” our team includes passionate and talented individuals from Google, IDEO, Harvard, Stanford, and Columbia. Our approach has been embraced by major employers across the country, including Costco and Iron Mountain, as well as leading health plans, such as Kaiser Permanente and Humana.
Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare diseases. Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders, reaching a total of over 20 therapies in various stages of development. The Company`s programs span across several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is poised to be the most meaningful precision genetic medicine company in the world and make a profound difference in the lives of patients suffering from rare neuromuscular diseases and other rare diseases.